• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

总前列腺特异性抗原和游离前列腺特异性抗原免疫测定之间的系统差异:使用帕辛和巴布洛克回归法进行比较

Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression.

作者信息

Serdarevic Nafija, Dabla Pradeep, Stanciu Adina Elena

机构信息

Institute for Clinical Chemistry and Biochemistry, University of Sarajevo Clinics Center, 71000 Sarajevo, Bosnia and Herzegovina.

Department of Biochemistry, G.B.Pant Institute of Postgraduate Medical Education and Research (GIPMER), GNCTD, Delhi, India.

出版信息

Indian J Clin Biochem. 2021 Apr;36(2):151-158. doi: 10.1007/s12291-019-0818-6. Epub 2019 Feb 13.

DOI:10.1007/s12291-019-0818-6
PMID:33867705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7994458/
Abstract

Recent studies have shown that there are systematic differences among total and free prostate-specificantigen (PSA) immunoassays. In this study we analyzedintermethod differences in total PSA (tPSA) and free PSA(fPSA) measurement using ARCHITECT 2000SR (Abbott Diagnostics) and COBAS E601 (Roche Diagnostics). A number of 160 blood samples were tested for tPSA and 50 samples for fPSA (selecting only sampleswith tPSA: 4.1-10.0 μg/L). Passing-Bablok regression analysis was used to compare the two analytical methods fortPSA, fPSA and percentage of fPSA (%fPSA). A strong correlation was noticed between ARCHITECT 2000SR and COBAS E601 for tPSA, fPSA and %fPSA (r between 0.94 and 0.99). Concentrations of tPSA and fPSA measured by COBAS E601 were higher thanthose measured by ARCHITECT 2000SR with a bias of 0.8 μg/L for tPSA and 0.14 μg/L for fPSA. Analyzing therelative difference between methods for fPSA and %fPSA, COBAS E601 exceed a 10% relative difference limit. Our study confirms that there are differences in measured concentrations of tPSA and fPSA byvarious commercial methods. Because clinical judgment on subsequent diagnostic procedures, such as prostatebiopsy, is based on tPSA and fPSA results, tests harmonization should be a priority.

摘要

近期研究表明,总前列腺特异性抗原(PSA)和游离PSA免疫测定之间存在系统性差异。在本研究中,我们使用ARCHITECT 2000SR(雅培诊断)和COBAS E601(罗氏诊断)分析了总PSA(tPSA)和游离PSA(fPSA)测量的方法间差异。对160份血样进行了tPSA检测,对50份血样进行了fPSA检测(仅选择tPSA为4.1 - 10.0μg/L的样本)。采用Passing - Bablok回归分析比较tPSA、fPSA和fPSA百分比(%fPSA)的两种分析方法。ARCHITECT 2000SR和COBAS E601在tPSA、fPSA和%fPSA方面呈现出强相关性(r在0.94至0.99之间)。COBAS E601测量的tPSA和fPSA浓度高于ARCHITECT 2000SR测量的浓度,tPSA偏差为0.8μg/L,fPSA偏差为0.14μg/L。分析fPSA和%fPSA方法之间的相对差异,COBAS E601超过了10%的相对差异限值。我们的研究证实,不同商业方法测量的tPSA和fPSA浓度存在差异。由于后续诊断程序(如前列腺活检)的临床判断基于tPSA和fPSA结果,检测方法的标准化应成为首要任务。

相似文献

1
Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression.总前列腺特异性抗原和游离前列腺特异性抗原免疫测定之间的系统差异:使用帕辛和巴布洛克回归法进行比较
Indian J Clin Biochem. 2021 Apr;36(2):151-158. doi: 10.1007/s12291-019-0818-6. Epub 2019 Feb 13.
2
Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.总前列腺特异性抗原(total PSA)、游离前列腺特异性抗原(free PSA)及游离前列腺特异性抗原百分比结果的方法间差异
Am J Clin Pathol. 2008 Jun;129(6):952-8. doi: 10.1309/JYBPMFNUF6EYY9TB.
3
Comparison of Architect i2000sr and Cobas e601 Systems for Determining Serum Human Chorionic Gonadotropin-Beta.Architect i2000sr系统与Cobas e601系统在测定血清β-人绒毛膜促性腺激素方面的比较
Clin Lab. 2016 Sep 1;62(9):1815-1820. doi: 10.7754/Clin.Lab.2016.160225.
4
Comparison of Three Immunoassays Systems for Determining Serum Estradiol.三种测定血清雌二醇免疫分析系统的比较
Clin Lab. 2019 Apr 1;65(4). doi: 10.7754/Clin.Lab.2018.180903.
5
Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management.管理前列腺特异性抗原检测方法间偏倚对活检转诊的影响:实现前列腺癌管理精准医学的关键。
Clin Chem Lab Med. 2022 Nov 2;61(1):142-153. doi: 10.1515/cclm-2022-0874. Print 2023 Jan 27.
6
Discordant prostate specific antigen test results despite WHO assay standardization.尽管有世界卫生组织的检测标准化,但前列腺特异性抗原检测结果仍不一致。
Int J Biol Markers. 2018 Aug;33(3):275-282. doi: 10.1177/1724600818754750. Epub 2018 May 8.
7
Analytical performance of the VITROS® Immunodiagnostic Products total PSA II and free PSA assays.VITROS®免疫诊断产品总前列腺特异性抗原II和游离前列腺特异性抗原检测的分析性能。
Clin Biochem. 2014 Sep;47(13-14):1323-5. doi: 10.1016/j.clinbiochem.2014.06.006. Epub 2014 Jun 15.
8
Measurement Differences Between Two Immunoassay Systems for LH and FSH: A Comparison of Roche Cobas e601 vs. Abbott Architect i2000sr.两种促黄体生成素(LH)和促卵泡生成素(FSH)免疫分析系统的测量差异:罗氏Cobas e601与雅培Architect i2000sr的比较
Clin Lab. 2018 Mar 1;64(3):295-301. doi: 10.7754/Clin.Lab.2017.170401.
9
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.血清中总前列腺特异性抗原和游离前列腺特异性抗原测量值与5种常用检测组合的互换性:最新进展
Clin Chem. 2006 Jan;52(1):59-64. doi: 10.1373/clinchem.2005.059170.
10
Variability of assay methods for total and free PSA after WHO standardization.世界卫生组织标准化后总前列腺特异性抗原(PSA)和游离PSA检测方法的变异性
Tumour Biol. 2014 Mar;35(3):1867-73. doi: 10.1007/s13277-013-1249-2. Epub 2013 Oct 4.

引用本文的文献

1
Technetium-99m-methylene diphosphonate single photon emission computed tomography/computed tomography combined with prostate-specific antigen/free prostate-specific antigen ratio for bone metastasis of prostate cancer.锝-99m-亚甲基二膦酸盐单光子发射计算机断层扫描/计算机断层扫描联合前列腺特异性抗原/游离前列腺特异性抗原比值用于前列腺癌骨转移的诊断
World J Clin Cases. 2024 Jul 16;12(20):4082-4090. doi: 10.12998/wjcc.v12.i20.4082.

本文引用的文献

1
New biomarkers for diagnosis and prognosis of localized prostate cancer.用于局限性前列腺癌诊断和预后的新型生物标志物。
Semin Cancer Biol. 2018 Oct;52(Pt 1):9-16. doi: 10.1016/j.semcancer.2018.01.012. Epub 2018 Jan 31.
2
The establishment and evaluation of a new model for the prediction of prostate cancer.一种预测前列腺癌新模型的建立与评估
Medicine (Baltimore). 2017 Mar;96(11):e6138. doi: 10.1097/MD.0000000000006138.
3
Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy.用于癌症诊断与治疗的放射性标记纳米颗粒。
Anticancer Agents Med Chem. 2017;17(3):333-354. doi: 10.2174/1871520616666160219162902.
4
PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.前列腺特异性抗原(PSA)、PSA衍生物、游离前列腺特异性抗原(proPSA)及前列腺健康指数在前列腺癌诊断中的应用
Turk J Urol. 2014 Jun;40(2):82-8. doi: 10.5152/tud.2014.94547.
5
Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations.是时候用前列腺健康指数(PHI)取代前列腺特异性抗原(PSA)了吗?更多证据表明,在不同人群中,PHI始终优于PSA。
BJU Int. 2015 Apr;115(4):500. doi: 10.1111/bju.12966.
6
Analytical performance of the VITROS® Immunodiagnostic Products total PSA II and free PSA assays.VITROS®免疫诊断产品总前列腺特异性抗原II和游离前列腺特异性抗原检测的分析性能。
Clin Biochem. 2014 Sep;47(13-14):1323-5. doi: 10.1016/j.clinbiochem.2014.06.006. Epub 2014 Jun 15.
7
Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods.
Clin Biochem. 2014 Jul;47(10-11):897-900. doi: 10.1016/j.clinbiochem.2014.03.027. Epub 2014 Apr 12.
8
Comparison of methods: Passing and Bablok regression.方法比较:Passing-Bablok 回归。
Biochem Med (Zagreb). 2011;21(1):49-52. doi: 10.11613/bm.2011.010.
9
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.哥德堡随机人群前列腺癌筛查试验的死亡率结果。
Lancet Oncol. 2010 Aug;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7. Epub 2010 Jul 2.
10
Prostate specific antigen for early detection of prostate cancer: longitudinal study.前列腺特异性抗原用于前列腺癌的早期检测:纵向研究
BMJ. 2009 Sep 24;339:b3537. doi: 10.1136/bmj.b3537.